2 Predictions for Pfizer in 2026

Is 2026 the year (NYSE: PFE) finally turns things around? The company has been struggling over the past few years due to poor financial results and looming patent cliffs. However, it has also made important moves that might start to pay off, possibly as early as 2026.

Are Pfizer's shares worth investing in heading into the new year? To try to answer that question, let's consider two things that might happen to the drugmaker in the next 12 months.

Pfizer has historically had a pretty strong presence in oncology, one of the largest therapeutic areas in the pharmaceutical industry. In the past few years, the company has made significant efforts to expand its presence in this market. It acquired Seagen, a smaller oncology specialist, for $43 billion, thereby gaining access to a substantial pipeline of investigational cancer therapies.

Continue reading

Source Fool.com